Glutamate and dopamine components in schizophrenia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The treatment of schizophrenia for the last half century has been with dopamine (DA) D 2 receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report found that the glutamate agonist LY404039 was effective in schizophrenia, suggesting a hypoglutamate state for the illness. Although phencyclidine psychosis also supports a hypoglutamate cause, assessing the basic and clinical findings shows that phencyclidine has DA D 2 agonist actions as well. Accurate Dreiding models of phencyclidine and the LY glutamate agonists precisely fit the known tetrahedral model of the D 2 receptor that accommodates all DA agonists. A further view is that metabotropic glutamate agonists also exert D 2 agonism, and their antipsychotic doses (about 100 mg/d) are predicted by their dissociation constants (about 20 nM) for D 2. Hence, the clinical antipsychotic action of a glutamate agonist may depend on its ability to interfere with DA neurotransmission by its DA partial agonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia
Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 2×
“More recently, one of these LY glutamate agonists, namely LY404039 (in the form of an oral prodrug, LY2140023), has been used to treat schizophrenia.(6) However, because LY404039 is essentially identical to LY379268, it appears reasonable to consider that LY404039 also has a DA partial agonist action, would interfere…”
MethodBidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons
Seamans, J. K., Gorelova, N., Durstewitz, D., & Yang, C. R. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-03628.2001 · Cited by 507 · cited 1×
“J Psychiatry Neurosci 2009;34(2) 149 influenced by the prefrontal cortex and hippocampus, DA alterations and enhanced release in the striatum could be secondary to glutamate disruptions in the prefrontal cortex and hippocampus.(39)”
Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
Morishima, Y., Miyakawa, T., Furuyashiki, T., Tanaka, Y., Mizuma, H., & Nakanishi, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500914102 · Cited by 148
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Willeit, M., Ginovart, N., Graff, A., Rusjan, P., Vitcu, I., Houle, S., Seeman, P., Wilson, A. A., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301400 · Cited by 107
Self-citation
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
“This includes phencyclidine psychosis [32,41].”
BackgroundMethodResultInfluentialSelf-citationDevelopmental vulnerability of synapses and circuits associated with neuropsychiatric disorders
Penzes, P., Buonanno, A., Passafaro, M., Sala, C., & Sweet, R. A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12261 · Cited by 125
Epigenetic changes at gene promoters in response to immune activation in utero
Tang, B., Jia, H., Kast, R. J., & Thomas, E. A. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.01.086 · Cited by 91
Metadata
- Authors
- Seeman, P.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2009-03
- Volume
- 34
- Issue
- 2
- Pages
- 143-149
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W4413981450
- Cited by
- 54
- References
- 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.